Opiranserin (VVZ-149) hydrochloride，一种非阿片类药物和非甾体抗炎止痛药，是 2 型甘氨酸转运蛋白 (GlyT2) 和 5-羟色胺受体2A (5HT2A) 的双重拮抗剂，IC50 分别为 0.86 和 1.3 μM。Opiranserin hydrochloride 对 rP2X3 有拮抗作用 (IC50=0.87 μM)。Opiranserin hydrochloride 可用于术后疼痛的研究。
| Cas No. | 1440796-75-7 |
| 别名 | VVZ-149 hydrochloride |
| 分子式 | C21H35ClN2O5 |
| 分子量 | 430.97 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain[1][2][3]. [1]. Oh J, et al. Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study. J Clin Pharmacol. 2018 Jan;58(1):64-73.
[2]. Nedeljkovic SS, et al. Randomised, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for postoperative pain following laparoscopic colorectal surgery. BMJ Open. 2017 Feb 17;7(2):e011035.
[3]. Pang MH, et al. A series of case studies: practical methodology for identifying antinociceptive multi-target drugs. Drug Discov Today. 2012 May;17(9-10):425-34. |
